In vivo mapping of cerebral small-vessel abnormalities in Parkinson's disease patients using USPIO-MRI at 3T.
In vivo mapping of cerebral small-vessel abnormalities in Parkinson's disease patients using USPIO-MRI at 3T.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Detroit, US · Author affiliation
Department of Neurology, Wayne State University, Detroit, MI, USA.Location evidence
London, CA · Author affiliation
Department of Clinical Neurological Sciences, Western University, London, ON, Canada.Location evidence
New York City, US · Author affiliation
Center for Biomedical Imaging, Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA.Location evidence
Bergen, NO · Author affiliation
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway; K.G. Jebsen Center for Translational Research in Parkinson's disease, University of Bergen, Bergen, Norway.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Conventional imaging techniques lack the resolution and sensitivity to adequately characterize cerebral small-vessel abnormalities (CSVA) in vivo. This study aimed to overcome these limitations and evaluate the feasibility of a novel MRI technique called Microvascular In-vivo Contrast Revealed Origins (MICRO), which uses an ultrasmall superparamagnetic iron oxide (USPIO) contrast agent (Ferumoxytol) to resolve the cerebral microvascular architecture with a level of anatomical and physiological detail not previously achievable in vivo. Fifty-nine Parkinson's disease (PD) patients underwent MICRO MRI based on susceptibility-weighted imaging (SWI). Three independent raters identified and categorized CSVAs as large developmental venous anomalies (DVAs), micro DVAs, engorged vessels, and diminished vessels. The location of each CSVA was documented, and its association with white matter hyperintensities (WMHs) was assessed. The MICRO imaging protocol demonstrated excellent inter-rater agreement for identifying these CSVAs. Our findings show a high prevalence of CSVAs in PD patients, with engorged vessels being the most common type (49.06% of subjects). Both engorged vessels (72.41%) and micro DVAs (81.82%) were highly associated with WMHs. CSVAs were most frequently observed in the periventricular white matter (n = 28), deep white matter (n = 32), and putamen (n = 14), suggesting a regional distribution pattern of detectable CSVAs. This work establishes MICRO as a feasible, reliable platform for in vivo microvascular mapping with potential applications in neurovascular research.